Navitoclax demonstrated meaningful clinical activity in CLL, but its usage was limited by the occurrence of thrombocytopenia regardless of the dose because of the inhibition of BCL-XL, which is a pro-survival protein relevant for circulating platelets [73]. Here, BCL2L1 is linked to B-cell chronic lymphocytic leukemia.